Upcoming webinar

Advancing testicular cancer management with ctDNA: Clinical utility of Signatera™ for MRD detection and surveillance

Date: Monday, May 11, 2026

Time: 5:00 PM - 6:00 PM ET | 2:00 PM - 3:00 PM PT

Webinar duration: 60 minutes

Registrants will receive a recording of the webinar approximately one week after the event.

Overview:

This webinar will review emerging clinical evidence supporting the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in germ cell tumors, including data demonstrating a significant association between ctDNA positivity and inferior event-free survival in both MRD and surveillance settings.

During this webinar, participants will gain insights into:

Clinical performance of ctDNA vs conventional serum tumor markers (AFP, hCG) in germ cell tumors
Association of ctDNA positivity with recurrence risk in MRD and surveillance settings
Integration of ctDNA into post-orchiectomy and post-chemotherapy management decisions
Case-based discussion illustrating real-world clinical application

Natera Honey Pot

Register Now:

First Name*

Last Name*

Email Address*

Job Title*

Phone*

Company Name*

Postal Code*

Country*

I am a*

Do you have any questions for the presenters that you would like to submit before the webinar?

Please fill in the field above only if you have specific questions. Otherwise, leave it blank.

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.

Hear from our speakers

John P. Sfakianos, MD

Professor of Urologic Oncology

Icahn School of Medicine at Mount Sinai

Urologic Oncologist, Genitourinary Malignancies

Nabil Adra, MD

Associate Professor of Medicine

Indiana University School of Medicine

Medical Oncologist, Genitourinary Malignancies

Moderator:

Ashley Wray, DMSc, MPH, PA-C

Medical Science Liaison,

Natera

Signatera™ has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2026 Natera, Inc. All Rights Reserved.

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com | Do Not Share My Personal Information | Privacy Policy